Insulin Lispro (Humalog) from Japan
Rapid-acting insulin analogue created by recombinant DNA technology with amino acid modifications for faster absorption. Falls under HTS 2937.12.00.00 as a structural analogue of insulin used primarily as a hormone for glycemic control. Qualifies as a chain-modified polypeptide hormone per chapter notes.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Submit FDA IND/BLA documentation; verify analogue structure matches declared sequence
• Use validated refrigerated shipping with temperature data loggers; insulin analogues are heat-sensitive
• Avoid bulk packaging declarations; pure API form stays in 2937, finished injectables move to 3004